Lundbeck Investor

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing, and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas such as depression, schizophrenia, Parkinson’s disease, and Alzheimer’s disease. According to the World Health Organization, WHO, more than 700 million cases of psychiatric and neurological disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionized the treatment options, but there remains a large unmet need for new and innovative therapeutics. Focus on R&D is the most important pillar in Lundbeck’s ambition to improve treatment for people living with psychiatric and neurological disorders. We are specialists in our area and have research facilities in Denmark and China, and more than 1,000 employees work in our R&D units. We cooperate closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions. Lundbeck employs approximately 5,300 people worldwide, 1,700 of whom are based in Denmark. We have employees in 55 countries, and our products are registered in more than 100 countries. We have production facilities in China, Denmark, France and Italy and research centers in Denmark and China.
Technology: Health Care, Health Diagnostics, Medical
Industry: Longevity Industry 2022
Headquarters: Valby, Hovedstaden, Denmark
Founded Date: 2000-01-01
Employees Number: 5001-10000
Funding Status: IPO
Investor Type: Undisclosed
Investment Stage: Undisclosed
Number Of Exits: 1
Acquisitions Number: 1
Investors Number: 1
Estimated Revenue: $500M to $1B
Last Funding Date: 2020-03-04
Last Funding Type: Grant

Visit Website
information@lundbeck.com
http://twitter.com/lundbeck
Register and Claim Ownership